Metric: Biotech stock values on a roller coaster ride

The nation's biotech industry continues to rack up some big losses overall, but steadily rising revenues are being ginned by a long lineup of newly approved products. That kind of good-news, bad-news scenario has put biotech stock indexes on a roller coaster ride, says The Washington Post, with big spikes followed by swift drops in values. The latest round of ups and downs has demonstrated yet again that investing in the biotech field can require nerves of steel.

- read this article from The Washington Post for more

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.